Serogroup B Meningococcal Disease Vaccine Challenge

Why has the vaccine for serogroup B meningococcal disease taken longer to develop?

  • Vaccines against meningococcal serogroups A, C, Y, and W have been developed using serogroup-specific capsular polysaccharides1
  • This approach has not been possible for serogroup B meningococcal disease, because its capsular polysaccharide is poorly immunogenic1

Pfizer’s research is focusing on meningococcal disease in adolescents and young adults.


Reference: 1. McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):234-252.